DYSIS Colposcopy on Test of Cure patients – DYSIS Medical

DYSIS Colposcopy on Test of Cure patients

DYSIS Colposcopy on Test of Cure patients

New DYSIS study published in Medicine.

An article presenting the results of a prospective audit with DYSIS colposcopy has been published in Medicine.

The study was conducted at the leading Northern Gynecologic Oncology Center (NGOC) at Queen Elizabeth Hospital, NHS Foundation Trust, Gateshead. The article discusses findings for women who underwent colposcopy due to a cytology negative and High-Risk HPV positive result (Failed Test of Cure) following prior LLETZ treatment for High-Grade cervical intraepithelial neoplasia (CIN). HPV triage as “Test of Cure” for patients with negative cytology, is a care pathway that was recently introduced in England replacing the pre-existing annual cytological follow-up for ten years. TOC was found to improve efficiency in studies preceding its introduction; nevertheless it represents a cohort of patients with unfamiliar characteristics for colposcopists.

This is the first published data, as well as the first to include dynamic spectral imaging (DSI, proprietary for DYSIS) mapping of the cervix, for this population. The results show that the sensitivity to correctly identify CIN lesions in the Test of Cure population is vastly superior with the use of the DYSISmap in comparison to standard colposcopy (80% versus 0%). Women that have been previously treated for high-grade CIN remain at an elevated risk for cervical cancer compared to the general population, therefore early detection and follow-up is vital.

“The Test of Cure population is for many reasons a rather challenging group for us clinicians; therefore any technology that could assist towards correct diagnosis and management is most welcome. These data are important for 2 reasons: Firstly because they indicate that in this group the percentage of underlying disease is potentially higher than previously identified and secondly because they show that DYSIS technology could correctly identify the areas of underlying disease on the regenerated cervical epitheliumsaid Dr Christina Founta, PhD, Consultant Gynaecologist and Diagnostics Lead at Musgrove Park Hospital, Taunton & Somerset NHS Foundation Trust, Taunton, UK

The full article can be accessed here.